進行した乳がんの治療におけるカピヴァサーチブの費用対効果:米国の医療の見通し
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
PubMedで要約を見る
まとめ
この要約は機械生成です。進行した乳がんの治療にカピヴァサーチブをフルヴェストラントに追加することは,現在の価格では費用対効果が高くありません. 米国医療制度に合わせた価格交渉が必要
科学分野
- 腫瘍学
- 健康 経済
- 薬学経済学
背景
- カピヴァサーチブとホルモン療法 (フルヴェストラント) の併用は,HR+/ HER2- 進行性乳がんの治療に承認されています.
- カピヴァサーチブとフルヴェストラントの効果はフルヴェストラント単独よりも優れていることがCapiTello-291試験で示されました.
研究 の 目的
- 米国におけるHR+/ HER2- 進行性乳がんに対するフルヴェストラント単独治療とカピヴァサーチブ併用の費用対効果を評価する.
- 支払者の視点から 経済的価値を評価する
主な方法
- 708人の参加者と3つの健康状態 (進行しない,進行する病気,死亡) のマルコフモデルが使用されました.
- CapiTello-291試験からのデータは,100,000ドル/QALYの支払意向の値を使用してモデルに情報を与えました.
- モデルの不確実性を評価するために,感度分析が行われました.
主要な成果
- ベースモデルは,0.62 QALY の増加コストを$79,117.66で示し,ICERは$128,283.61/QALYでした.
- カピヴァサーチブとフルヴェストラントの費用対効果は,$130,000/QALYで50%で,$500,100/QALYで100%であった.
結論
- フルヴェストラントにカピヴァサーチブを添加することは,現在の価格で,米国保健医療システムにおけるHR+/ HER2- 進行性乳がんの治療に費用対効果的ではありません.
- カピヴァサーチブの価格に関する交渉は,費用対効果を向上させ,標準治療に統合するために不可欠です.
関連する概念動画
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
The Kaplan-Meier estimator is a non-parametric method used to estimate the survival function from time-to-event data. In medical research, it is frequently employed to measure the proportion of patients surviving for a certain period after treatment. This estimator is fundamental in analyzing time-to-event data, making it indispensable in clinical trials, epidemiological studies, and reliability engineering. By estimating survival probabilities, researchers can evaluate treatment effectiveness,...